Home / Technology & Devices (page 20)

Technology & Devices

Daiichi Sankyo & Glycotope Enter Option Agreement for Antibody Drug Conjugate Strategic Collaboration and Licensing

TOKYO and BASKING RIDGE, N.J., and BERLIN, Oct. 30, 2017 /PRNewswire/ — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Glycotope GmbH (hereafter, Glycotope) have signed an option agreement for future strategic collaboration and licensing to develop an antibody drug conjugate (ADC) by combining Daiichi Sankyo’s proprietary ADC technology with …

Read More »

New Study: ‘Double Decker’ Antibody Technology Fights Cancer

JUPITER, Fla., Oct. 25, 2017 /PRNewswire-USNewswire/ — Scientists from the Florida campus of The Scripps Research Institute (TSRI) have created a new class of antibody-drug conjugates (ADCs), using a versatile “double decker” technology that ties antibodies and a drug together to produce highly potent pharmaceuticals for cancer therapy. The new …

Read More »

Veracyte Presents New Data Validating Accuracy of BRAF V600E and Parathyroid Tissue Classifiers

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (NASDAQ: VCYT) announced that data presented at the 87th Annual Meeting of the American Thyroid Association (ATA) being held October 18-22 in Victoria, BC, Canada demonstrate the accuracy of identification of BRAF V600E and parathyroid tissue through new classifiers developed in conjunction with the next-generation Afirma …

Read More »

Astellas and Universal Cells Enter Collaboration Utilizing Universal Donor Cell Technology

TOKYO, Oct. 19, 2017 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Universal Cells, Inc. (CEO: Claudia Mitchell, “Universal Cells”) today announced that Astellas Institute for Regenerative Medicine (“AIRM”) and Universal Cells have entered into an exclusive worldwide license agreement to research, develop and …

Read More »

AbbVie and Harpoon Therapeutics Enter Immuno-Oncology Research Collaboration

NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Oct. 18, 2017 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Harpoon Therapeutics, a biotechnology company developing novel T-cell recruiting biologic therapies, announced today that they have entered an immuno-oncology research collaboration. The goal of the collaboration is to incorporate …

Read More »

Lilly and CureVac Enter Global Collaboration to Develop mRNA Cancer Vaccines

INDIANAPOLIS and TÜBINGEN, Germany, Oct. 18, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and CureVac AG have announced a global immuno-oncology collaboration focused on the development and commercialization of up to five potential cancer vaccine products based on CureVac’s proprietary RNActive® technology. The companies will use messenger RNA (mRNA) technology that targets tumor neoantigens for a more robust anti-cancer …

Read More »

New Technique Scours the Genome for Genes that Combat Disease

Using a modified version of the CRISPR genome-editing system, MIT researchers have developed a new way to screen for genes that protect against specific diseases. CRISPR is normally used to edit or delete genes from living cells. However, the MIT team adapted it to randomly turn on or off distinct …

Read More »

Scientists Develop ‘Body-On-A-Chip’ System to Accelerate Testing of New Drugs

WINSTON-SALEM, NC, Oct. 5, 2017 – Using the same expertise they’ve employed to build new organs for patients, scientists at Wake Forest Institute for Regenerative Medicine and colleagues have engineered micro hearts, lungs and livers that can potentially be used to test new drugs. By combining the micro-organs in a …

Read More »

Ligand to Acquire Crystal Bioscience, Gaining Complementary Antibody Technology

SAN DIEGO & EMERYVILLE, Calif.–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Crystal Bioscience, Inc. (Crystal) announce the signing of a merger agreement whereby Ligand will acquire Crystal, a leader in avian genetics and the generation of fully-human therapeutic antibodies. Under the terms of the agreement, Ligand will pay Crystal shareholders $25 million …

Read More »

FDA Improves Access to Reports of Adverse Drug Reactions

The U.S. Food and Drug Administration today launched a new user-friendly search tool that improves access to data on adverse events associated with drug and biologic products through the FDA’s Adverse Event Reporting System (FAERS). The tool is designed to make it easier for consumers, providers, and researchers to access this …

Read More »